Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis
Authors:
- E. G. YurkinaEYE. G. Yurkina
- D. Yu. EfimovDED. Yu. Efimov
- S. I. KrivenkoSKS. I. Krivenko
- E. A. PrimakovaEPE. A. Primakova
- E. A. NazarovaENE. A. Nazarova
- A. A. SymanovichASA. A. Symanovich
- N. I. DedyulyaNDN. I. Dedyulya
- В. В. СмольниковаВСВ. В. Смольникова
- E. A. YanushevskayaEYE. A. Yanushevskaya
- I. A. RomanovaIRI. A. Romanova
- V. V. SazanovetsVSV. V. Sazanovets
- D. N. SadovskiyDSD. N. Sadovskiy
Open Access
- 8 January 2025
- journal article
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 68 (6) , 483-492
Abstract
Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.Keywords
This publication has 15 references indexed in Scilit:
- Advancements in mesenchymal stem cell therapy for liver cirrhosis: Unveiling origins, treatment mechanisms, and current research frontiersTissue and Cell, 2023
- The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic ApplicationsBiological and Pharmaceutical Bulletin, 2023
- Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarizationStem Cell Research & Therapy, 2021
- Bone Marrow Mesenchymal Stem Cells in Acute‐on‐Chronic Liver Failure Grades 2 and 3: A Phase I‐II Randomized Clinical TrialCanadian Journal of Gastroenterology and Hepatology, 2021
- Mesenchymal stem cells accelerate liver regeneration in acute liver failure animal modelBiomedical Research and Therapy, 2018
- Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosisHepatobiliary & Pancreatic Diseases International, 2016
- Mesenchymal Stromal Cells Engineered to Produce IGF-I by Recombinant Adenovirus Ameliorate Liver Fibrosis in MiceStem Cells and Development, 2015
- Concise Review: Therapeutic Potential of Mesenchymal Stem Cells for the Treatment of Acute Liver Failure and CirrhosisStem Cells, 2014
- Human amnion‐derived mesenchymal stem cells are a potential source for uterine stem cell therapyCell Proliferation, 2008
- Homing of Mesenchymal Stem CellsTransfusion Medicine and Hemotherapy, 2008